INCHINNAN, Scotland, Nov. 5, 2019 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced that it is investing nearly $24 million in its Inchinnan, Scotland, site to expand global bioproduction capabilities with additional large-volume liquid manufacturing capacity for cell culture media.
Thermo Fisher's high-quality liquid products, including cell culture media, supplements, process liquids, water and buffers, are used throughout the upstream and downstream bioprocessing workflow.
"More and more customers are outsourcing their liquid manufacturing to ensure the highest quality while delivering efficiency," said Cory Stevenson, president of Thermo Fisher's bioproduction business. "This investment will expand capabilities and expertise at our existing cell culture manufacturing center of excellence in the UK to meet growing customer demand for our industry-leading bioproduction products."
The Inchinnan site expansion is expected to be completed by June 2021.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.